Previous 10 | Next 10 |
WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Sen...
A vote is like a rifle: its usefulness depends upon the character of the user ." - Theodore Roosevelt Today, we revisit a 'Busted IPO' we looked at back in the second half of 2018. The company has done a good job advancing its pipeline. A full investment analysis follows in the paragr...
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a Key Opinion Leader (KOL) breakfast on maintenance therapy of adult patie...
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Sen...
Chiasma, Inc. (CHMA) Q2 2019 Results Conference Call August 8, 2019 5:00 PM ET Company Participants Glenn Garmont – Investor relations Raj Kannan – Chief Executive Officer Bill Ludlam – Senior Vice President-Clinical Development and Medical Affairs Mark Fit...
Chiasma (NASDAQ: CHMA ): Q2 GAAP EPS of -$0.25 beats by $0.04 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA ® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED enrollment complete; topline data expected in second half 2020 Completes common stock offering for n...
WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Thursda...
Chiasma ( CHMA ) announced that it had achieved positive results in a Phase 3 study using octreotide capsules (Mycapssa) for treatment of adults with acromegaly. This positive Phase 3 data will allow the biotech to file an NDA for its drug candidate in this indication by the end of 2019,...
Chiasma Inc. ( CHMA ) shares rose over 30% recently, buoyed by favorable results from the Phase 3 clinical trial for its octreotide capsules, conditionally trade-named drug Mycapssa, for the maintenance treatment of adults with acromegaly. Acromegaly is a hormone disorder that typically de...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...